Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities by Lemke, Krzysztof et al.
Induction of unique structural changes in
guanine-rich DNA regions by the triazoloacridone
C-1305, a topoisomerase II inhibitor with
antitumor activities
Krzysztof Lemke
1,4, Marcin Wojciechowski
1, William Laine
2, Christian Bailly
2,
Pierre Colson
3, Maciej Baginski
1, Annette K. Larsen
4 and Andrzej Skladanowski
1,*
1Laboratory of Cellular and Molecular Pharmacology, Department of Pharmaceutical Technology and Biochemistry,
Gdansk University of Technology, Gdansk, Poland,
2INSERM U-524 et Laboratoire de Pharmacologie Antitumorale
du Centre Oscar Lambret, IRCL, 59045 Lille Cedex, France,
3Biospectroscopy and Physical Chemistry Unit,
Department of Chemistry and Natural and Synthetic Drugs Research Center, University of Lie `ge, Sart-Tilman,
4000, Lie `ge, Belgium and
4Group of Biology and Pharmacogenetics of Human Tumors, INSERM U673,
Universite ´ Pierre et Marie Curie (UPMC-Paris 6), Ho ˆpital Saint-Antoine, Paris, 75571 Paris 12, France
Received September 8, 2005; Revised and Accepted September 29, 2005
ABSTRACT
We recently reported that the antitumor tria-
zoloacridone, compound C-1305, is a topoisomerase
II poison with unusual properties. In this study we
characterize the DNA interactions of C-1305 in vitro,
in comparison with other topoisomerase II inhibitors.
Our results show that C-1305 binds to DNA by inter-
calation and possesses higher affinity for GC- than
AT-DNA as revealed by surface plasmon resonance
studies. Chemical probing with DEPC indicated that
C-1305 induces structural perturbations in DNA
regions with three adjacent guanine residues.
Importantly, this effect was highly specific for C-
1305 since none of the other 22 DNA interacting
drugs tested was able to induce similar structural
changesinDNA.CompoundC-1305inducedstronger
structural changes in guanine triplets at higher pH
which suggested that protonation/deprotonation of
the drug is important for this drug-specific effect.
Molecularmodelinganalysispredictsthatthezwitter-
ionic form of C-1305 intercalates within the guanine
triplet,resultinginwideningofbothDNAgroovesand
aligning of the triazole ring with the N7 atoms of gua-
nines.OurresultsshowthatC-1305bindstoDNAand
inducesveryspecificandunusualstructuralchanges
inguaninetripletswhichlikelyplaysanimportantrole
in the cytotoxic and antitumor activity of this unique
compound.
INTRODUCTION
Triazoloacridone C-1305 belongs to a large group of acridine
derivatives that have been synthesized at Gdansk University of
Technologyinasearchfornewantitumorcompounds(1).This
compound showed potent antitumor activity toward a wide
range of different experimental tumors in vitro and in vivo
including both murine and human colon carcinomas (2). The
mechanism of action of C-1305 is currently under extensive
investigation. Our recent studies show that C-1305 is a DNA
topoisomerase II inhibitor which stabilizes covalent com-
plexes between DNA and the enzyme (3). Interestingly, at
cytotoxic doses C-1305 produces only low levels of unusually
toxic cleavable complexes compared to classic topoisomerase
II inhibitors such as amsacrine (m-AMSA). Another unusual
feature of C-1305 is its potent cytotoxic activity toward
PARP1-deﬁcient cells in striking contrast to other topoiso-
merase II inhibitors that are less cytotoxic toward cells with
compromised PARP1 function (4).
DNA topoisomerase II is an essential nuclear enzyme that
regulates DNA topology and chromatin organization in living
cells (5). The enzyme relieves torsional stress in DNA by
controlled breakage-reunion of both DNA strands and passage
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doi:10.1093/nar/gki904of a DNA segment through the strand breaks. All topoiso-
merase II directed agents interfere with at least one step of
the catalytic cycle and thus classify as topoisomerase
inhibitors. Compounds that stabilize the covalent enzyme
intermediate (cleavable complex) between DNA and topoiso-
merase II are traditionally called topoisomerase poisons (6),
while agents that act on other steps of the catalytic cycle are
called catalytic inhibitors (7). The majority of clinically used
topoisomerase II inhibitors are topoisomerase poisons.
Although topoisomerase II inhibitors are among the most
effective antitumor drugs that are used in the treatment of
human tumors (8), the mechanistic basis for their activity is
not fully elucidated. Inhibition of DNA topoisomerase II by
antitumor drugs leads to many different cellular effects includ-
ing DNA strand breaks through the conversion of cleavable
complexes into direct DNA lesions during transcription and
replication. Although the formation of DNA damage is con-
sidered as a crucial event in the cytotoxic activity of topoiso-
merase II inhibitors, perturbations of DNA topology and
chromosome condensation during G2 and mitosis may also
participate in the cytotoxic and antitumor effects of these
agents (9). Recent results suggest that topoisomerase II
inhibitors might work as transcriptional modulators, in par-
ticular with respect to the expression of genes responding to
environmental changes (10).
Ithaslongbeen debated whether topoisomerase IIinhibitors
induce enzyme-mediated DNA damage in speciﬁc DNA
regions such as MAR sequences (11). Many factors could
inﬂuence the drug-induced topoisomerase II-mediated
sequence-speciﬁc DNA cleavage including the enzyme’s
binding site preference, the sequence preference for drug–
DNA-binding, the binding site accessibility for topoisomerase
II or drug-induced changes in DNA structure/topology (12).
Speciﬁc cleavage at deﬁned DNA sites by topoisomerase II in
the presence of its inhibitors could be important from at least
two perspectives. First, it could explain the chromosome band-
speciﬁc DNA damage that is observed in patients treated with
the topoisomerase II inhibitor etoposide (13). Second, differ-
enttopoisomeraseIIinhibitorscouldhavedistincteffectonthe
DNA transcription pattern of drug-treated cells, depending on
where and to which extent region-speciﬁc DNA cleavage is
induced. Topoisomerase II inhibition principally interferes
with DNA transcription due to the presence of immobilized
cleavable complexes that arrest the progression of the tran-
scription machinery (14). It may also result from accumulation
of superhelical tension ahead of the transcription complex that
prevents further progression of the RNA polymerase (15). We
would predict such region-speciﬁc transcriptional modiﬁca-
tions to be particularly important for topoisomerase II
inhibitors with strong DNA-binding.
We speculated that the pronounced toxicity of
triazoloacridone-induced DNA damage might be due to stimu-
lation of cleavable complexes in speciﬁc DNA regions. In this
study, we show that C-1305 binds to DNA by intercalation and
induces unusual structural changes in DNA regions with gua-
nine triplets. Comparison with other topoisomerase inhibitors
and different DNA interacting agents showed that the struc-
tural perturbations in guanine-rich regions were speciﬁc for
C-1305. We also characterized the structural elements of the
triazoloacridones that are responsible for this effect and built a
model to illustrate this feature.
MATERIALS AND METHODS
Drugs and chemicals
All triazoloacridone derivatives and m-AMSA were synthe-
sized by Dr Barbara Horowska at the Department of Pharma-
cologicalTechnologyandBiochemistry,GdanskUniversityof
Technology, Poland (see Figure 1 and Table 1 for chemical
structures). Triazoloacridones (free bases) were used from 10
mM stock solutions prepared in 0.2% lactic acidin water (v/v),
m-AMSA was used from 10 mM stock solutions prepared in
water and kept at  20 C until use. Radiolabeled [a-
32P]-
dATP (3000 Ci/mmol), was purchased from Amersham Bio-
sciences AB (Uppsala, Sweden). Calf thymus DNA, double-
stranded polymers [poly(dA–dT)]2 and [poly(dG–dC)]2 were
purchased from Sigma Chemicals Co. (St Louis, MO). All
other reagents were of analytical grade and obtained either
from Sigma or from the local purchaser.
Figure 1. Chemical structures of triazoloacridones C-1305 and C-1533.
Table 1. Chemical structures of selected triazolo- and imidazoacridone
derivatives, and their effect on stabilization of the DNA secondary structure
Compound n R1 R2 R3 X DTm ( C)
a
ctDNA
DTm ( C)
b
[poly(dA–dT)]2
C-1303 2 CH3 OH H N 8.9 ± 0.1 20.1 ± 1.4
C-1305 3 CH3 OH H N 11.9 ± 0.7 25.1 ± 0.1
C-1296 2 CH3 CH3 H N 9.8 ± 0.6 20.9 ± 1.6
C-1533 2 CH3 OH CH3 N 7.4 ± 0.4 18.5 ± 0.9
C-1297 3 CH3 CH3 H N 12.1 ± 0.1 23.7 ± 1.6
C-1298 2 CH3 OCH3 H N 10.1 ± 0.1 23.0 ± 2.0
C-1299 3 CH3 OCH3 H N 7.1 ± 0.7 10.8 ± 2.6
C-1234 3 CH3 H H N 5.6 ± 0.9 5.4 ± 2.8
C-1293 2 CH2CH3 OH H N 6.1 ± 0.9 15.8 ± 0.7
C-1371 3 CH3 OH H C 8.1 ± 0.1 15.4 ± 4.4
(nucleotide) ratio of 0.5. Results are presented as means ± SD.
Ten different imidazo- and triazoloacridone derivatives were chosen for
structure–activity relationship studies using chemical probing and melting
temperature measurements. Bold face indicates the lead compound which
induces unusual structural changes at guianine-triplets.
aMelting temperatures determined for calf thymus DNA in the presence of
the studied compounds, the drug–DNA (nucleotide) ratio was 0.5, results are
presented as means ± SD.
bMelting temperatures for the [poly(dA–dT)]2 DNA polymer at a drug–DNA
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temperature studies
Absorption spectra and melting curves were determined using
an Uvikon 943 spectrophotometer (Kontron) coupled to a
Neslab RTE111 cryostat or CaryBio 300 spectrophotometer
coupled to a Peltier system (Varian). Titrations of the drug
with DNA covering a large range of DNA-phosphate/drug
ratios, were performed with ﬁxed drug concentration (20 mM)
and increasing concentrations of DNA substrates (in base
pairs): for ctDNA 7–140 mM, 3–60 mM for poly(dA–dT)
and poly(dG–dC). The experiments were conducted at 25 C
in BPE buffer pH 7.1 (6 mM Na2HPO4, 2 mM NaH2PO4 and
1 mM EDTA). DNA substrates were included in reference
samples.
For each series of Tm measurements, 12 samples were
placed in a thermostatically controlled cell-holder, and the
quartz cuvettes (10 mm pathlength) were heated by circulating
water. The measurements were performed in BPE buffer. The
temperature inside the cuvette was controlled with a platinum
probe and increased over the range 20–100 C with a heating
rate of 1 C/min. The ‘melting’ temperature Tm was calculated
as the mid-point of the hyperchromic transition curves.
Circular dichroism (CD)
The CD spectra were obtained with a J-810 Jasco spectropo-
larimeter at 20 C controlled by a PTC-424S/L Peltier type cell
changer (Jasco). A quartz cell of 10 mm path length was used
to obtain spectra from 500 to 230 nm with a resolution of
0.2 nm. Titrations of the drug with DNA, covering a large
range of P/D, were performed with ﬁxed drug concentration
(50 mM) and increasing concentrations of DNA substrates:
for ct DNA 14–270 mM, for poly(dA–dT) and poly(dG–dC)
6–80 mM, until no further changes in drug–DNA spectra were
observed. All the measurements were performed in 1 ml of
BPE buffer at 25 C.
Electric linear dichroism (ELD)
ELD measurements were performed with a computerized
optical measurement system using the procedures described
previously (16,17). All experiments were conducted with a
10 mm pathlength Kerr cell having 1.5 mm electrode separa-
tion. The samples were oriented under an electric ﬁeld strength
varyingfrom1to14kV/cm.Thedrugundertestwas present at
10 mM concentration together with the DNA at 200 mM con-
centration unless stated otherwise. This electro-optical method
has proved particularly useful to determine the orientation
of the drugs bound to DNA. It has the additional advantage
that it senses only the orientation of the polymer-bound ligand
since the free ligand is isotropic and does not contribute to the
signal.
Surface plasmon resonance
Bindingandkinetics measurements were performed with BIA-
core 3000 system and streptavidin coated sensor chips (CM-5
chips from BIAcore) as described previously (18). Two
50-biotin-labeled DNA hairpins (PAGE puriﬁed; Eurogentec,
Belgium) were used (hairpin loop underlined): d(biotin-CAT-
ATATATCCCCATATATATG) and d(biotin-CGCGCGCG-
TTTTCGCGCGCG). All procedures for binding studies
were automated as methods using repetitive cycles of sample
injection and regeneration. Steady-state binding analysis was
performed with multiple injections of different compound
concentrations over the immobilized DNA surfaces for a
9 min period at a ﬂow rate of 20 ml min
 1 at 25 C. Drug
solutions at concentrations ranging from 0.01 to 25 mM
were prepared in ﬁltered and degassed buffer by serial dilu-
tions from stock solution and were injected from 7 mm plastic
vials with pierceable plastic crimp caps (BIAcore Inc.). In all
cases, the DNA surface was regenerated by buffer ﬂow during
30 min without additional regeneration agents.
Average ﬁtting of the sensorgrams at the steady-state level
was performed with the BIAevaluation 3.0 program by ﬁtting
data from the steady-state regions to a multiple equivalent site
model using Kaleidagraph with the following equation.
r ¼ n · K · Cfree= 1 þ K · Cfree ðÞ
where K, the microscopic binding constant, is one variable to
ﬁt, r represents mol bound compound per mol DNA hairpin
duplex, Cfree is the concentration of the compound in equilib-
rium with the complex and is ﬁxed by the concentration in the
ﬂow solution and n is the number of compound binding sites
on the DNA duplex. The r values were calculated by the ratio
RU/RUmax, where RU is the steady-state response at each
concentration and RUmax is the predicted RU for binding of
a compound to the DNA in a ﬂow cell. Global kinetic ﬁtted to
the sensorgrams to obtain association and dissociation kinetics
constants were done using BIAevaluation software and an
equivalent site interaction model.
Purification and radiolabeling of DNA
restriction fragments
The 176 bp DNA fragment was prepared by 30 end
32P-
labeling of a EcoRI–PvuII (Promega) double digest of the
pBS plasmid (Stratagene, La Jolla, CA) using [a-
32P]dATP
(Amersham) and avian myeloblastosis virus reverse transcrip-
tase (Roche). Digestion products were separated on a 6%
polyacrylamide gel under native conditions in Tris–borate/
EDTA-buffered solution [89 mM Tris–borate (pH 8.3) and
1 mM EDTA). After autoradiography, DNA bands were
excised, crushed and eluted overnight in 500 mM ammonium
acetate and 10 mM magnesium acetate at 37 C. This suspen-
sion was ﬁltered through a 0.22 mm ﬁlter (Millipore Corpora-
tion, Bedford, MA) and the DNA was precipitated with
ethanol. After washing with 70% ethanol and vacuum drying
of the precipitate, the labeled DNA was dissolved in 10 mM
Tris–HCl (pH 7.0) containing 10 mM NaCl.
DNase I footprinting
Bovine pancreatic deoxyribonuclease I (DNase I, Sigma
Chemical Co.) was stored as a 7200 U/ml solution in
20 mM NaCl, 2 mM MgCl2, 2 mM MnCl2 (pH 8.0). The
stock solutions of DNase I were kept at  20 C and freshly
diluted to the desired concentration immediately before
use. Footprinting experiments were performed essentially as
described previously (19,20). Brieﬂy, reactions were con-
ducted in a total volume of 10 ml. For each sample,  3000
c.p.m. of radiolabeled DNA was used which corresponds to
 1 ng DNA. Samples (2 ml) of the labeled DNA fragment
were incubated with 6 ml of the buffered solution contain-
ing the ligand at appropriate concentration. After 15 min
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binding reaction, the digestion was initiated by the addition of
2 ml of a DNase I solution whose concentration was adjusted
to yield a ﬁnal enzyme concentration of  0.01 U/ml in the
reaction mixture. The reaction was stopped by freeze-drying
after 3 min. Samples were lyophilized and dissolved in 5 mlo f
an 80% formamide solution containing tracking dyes. The
DNA samples were then heated at 90 C for 3 min and chilled
in ice for 3 min before electrophoresis.
DEPC chemical probing
Chemical probing experiments were performed essentially as
described previously (21,22). Brieﬂy, DEPC (diethylpyrocar-
bonate, Sigma) reactions were conducted in a total volume of
20 ml. Samples (2 ml) of the labeled DNA fragment were
incubated with 18 ml of ligand in 10 mM Tris–HCl/NaCl
(pH 7.5). After 10 min incubation at 4 C to ensure equilibra-
tion of the binding reaction, the reaction was initiated by the
addition of 1 ml of DEPC solution and continued on ice with
intermittent mixing. After 15 min the reaction was stopped by
addition of 2 ml of 3 M sodium acetate and DNA precipita-
tion with 70% ethanol. Samples were lyophilized and applied
to DNA digestion with piperidine (30 ml of 1M solution
in water) at 90 C for 10 min. Samples were then lyophilized
and re-suspended in 5 ml of 80% formamide solution con-
taining tracking dyes, heated and resolved by PAGE under
denaturating conditions (0.3 mm thick gels and 8% acrylamide
containing 8 M urea). After electrophoresis ( 1.5 h at 55 W/
1600 V in Tris–Borate-EDTA-buffered solution and BRL
sequencing apparatus model S2), gels were soaked in 10%
acetic acid for 10 min, transferred onto Whatman 3 MM
paper, and dried under vacuum at 80 C. A Molecular
Dynamics 425E PhosphorImager system was used to collect
data from the storage screens exposed to dried gels overnight
at room temperature. Base line-corrected scans were analyzed
by integrating all the densities between two selected bound-
aries using ImageQuant software (version 3.3, Molecular
Dynamics). Each resolved band was assigned to a particular
band within the DNA fragments by comparison of its position
relative to sequencing standards generated by treatment of the
DNA with dimethyl sulphate followed by piperidine-induced
cleavage at the modiﬁed guanine bases in DNA (G-track).
Competition dialysis assay
The binding afﬁnity of C-1305 to different DNA substrates
was determined as described (23). For each competition dial-
ysis assay, 250 ml of low salt (10 mM NaCl) BPE buffer pH
7.1 (6 mM Na2HPO4, 2 mM NaH2PO4 and 1 mM EDTA)
containing 5 mM C-1305 was used. Oligonucleotides contain-
ing comparable GC content (50%) were purchased from Ther-
moElectron (see Table 2 for sequences). All substrates were
high-performance liquid chromatography (HPLC)-puriﬁed,
annealed in high salt BPE buffer, and dialyzed into BPES
buffer for 24 h at room temperature. All measurements
were performed using constant oligonucleotide concentration
(75 mM per bp), in a 100 ml Slide-A-Lyzer MINI dialyzer unit
with a 3500 Da molecular weight cut-off membranes (Pierce,
Rockford, IL) and continuous stirring for 24 h at room tem-
perature. After equilibration, SDS was added to each sample to
1% ﬁnal concentration and the drug concentrations were
determined by measuring the absorbance with a CaryBio
300 spectrophotometer (Varian) at 421 nm for both com-
pounds. The fraction of DNA-bound drug was calculated as
the difference between total drug concentration and unbound
(free) drug concentration.
Molecular modeling
Atomic coordinates of a 10mer double-stranded DNA
sequence: 50-GCGTGGGACC-30, containing a G-triplet,
wereobtainedfromitsX-raystructure(NucleicAcidDatabase,
accession no. pdt055). The structure was ﬁxed for missing
atoms (both heavy and hydrogen atoms) and the terminal
nucleotides were patched with hydroxyl groups to obtain inte-
ger charge model (i.e.  18). The resulting DNA substrate was
neutralized with sodium counterions and solvated with water
molecules in a 15 s box. The complete system was optimized
through molecular mechanics minimization of the global
energy function and then molecular dynamics simulation
was performed for the total time of 10 ns. The NPT ensemble
withisotropicpressureandthermalcouplingwasimplemented.
TheCHARMM27(24)forceﬁeldwithinNAMD(25)molecu-
lar dynamics engine was used with 11 s cut-off distance for
non-bondinginteractionsandParticleMeshEwaldsummation.
Theintegratorwassetto2fsanddatawerecollectedevery1ps.
The relaxed DNA structure obtained after 3 ns of MD simu-
lationwasthenusedtobuildC-1305:DNAcomplex.Thestruc-
ture of C-1305 was constructed using Quanta molecular
modeling package (Accelrys, San Diego, CA), where partial
charges were obtained by Merz–Kollman electrostatic ﬁtting
procedure from optimized B3LYP/6-31+G(df,p) ab initio cal-
culations within Gaussian 03 program. We also calculated
macroscopic pKa values of triazoloacridones in a broad
range of pH. For this purpose, we submitted all data to the
SPARC (Predictive Modeling System) online server at the
U.S. Environmental Protection Agency (Research Triangle
Park, NC) which previously has enabled correct estimation
of pKa values for more than 4000 organic compounds (26).
Calculated macroscopic pKa values were in agreement with
the values obtained from analyses of drug protonation based
on changes in UV-VIS spectra (Zoﬁa Mazerska, unpublished
data).Basedonallgathereddata,wefoundthatthezwitterionic
formofC-1305,withaprotonatedterminalnitrogenatominthe
side chain and a deprotonated hydroxyl oxygen in the planar
chromophore, was the most abundant form at pH close to
physiological and higher (pH > 7.5).
Table 2. Sequence of double-stranded DNA oligonucleotides used in melting
temperature studies and competition dialysis assays (only the upper strand
sequence is shown)
Oligonucleotides Sequence Tm ( C)
cGGGc 50-ATTCCGGGCTATATACGGGCCTAA-30 53.4 ± 0.1
aGGGa 50-GCAAAGGGAAACTGAAGGGAAACG-30 52.8 ± 0.2
tGGGt 50-GCAATGGGTTACTGATGGGTTACG-30 52.7 ± 0.5
cGGGa 50-AGTGCGGGATATATGCGGGATTGA-30 54.5 ± 0.4
GcGcG 50-TAATGCGCGCTATTACGCGCGATA-30 59.3 ± 0.5
cGaGc 50-AGTACGAGCATCCTACGAGCATTG-30 55.5 ± 0.6
CGtGc 50-AGTACGTGCATCCTACGTGCATTG-30 56.0 ± 0.1
Tmvaluescorrespondtoempiricallydeterminedmeltingtemperaturesofstudied
oligonucleotides in BPES buffer, pH 7.1. Bold face indicates potential DNA
binding/interaction sites for C-1305.
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calated compound in two different positions, were prepared in
the same manner as for DNA alone. Resulting trajectories
became a source for further analysis and calculations of static
properties for studied systems. To evaluate which of the inter-
calation sites is favored by the compound, an Molecular
Mechanics–Poisson Boltzmann Solvent Accessible (MM–
PBSA) approach was used, which was described in detail
previously (27). In this procedure, MM–PBSA is the sum
of energy contributions of bonds, angles, dihedrals, Coulomb
and Van der Waals interactions (MM part), the solvation
energy obtained from continuum solvent calculations (PB
part) and non-polar hydrophobic energy correlated with Solv-
ent Accessible surface area (SA part). The MM–PBSA energy
should be regarded only as the approximation of free energy
since it does not include explicit entropy terms. However, such
approach gives a good estimate of the differences in binding
constants of the two systems, where all parts either do not
change their conformations or change in a similar way. In both
cases, entropic contributions can be neglected and MM–PBSA
energy is correlated with binding constants, according to the
Equation 1.
DEMM PBSA   DDG ¼  RT lnDK 1
where DEMM–PBSA is a difference between total MM–PBSA
energy of two ligand–DNA complexes with different positions
of the drug, DDG is a difference between free energy of two
ligand–DNA complexes with different positions of the drug in
drug–DNA complex, and DK is a difference between ligand–
DNA-binding constants with two different intercalation sites.
Our own protocols to calculate MM–PBSA energy were
used as described previously (28). Each selected simulation
frame from MD was minimized with GB continuum model
(20 steps of steepest descent and 200 steps of conjugate gra-
dients algorithm) to avoid steric hindrances that could occur
during MD simulations. The MM contribution was calculated
using CHARMM 27 software and force ﬁeld (29), solvation
andnon-polarenergywascalculatedusingtheUHBDprogram
(30).Changesinmolecularelectrostaticpotential(MEP)ofthe
DNA upon drug intercalation were calculated with APBS
software package (31). Final analyses and plots were done
by Visual Molecular Dynamics software package (32).
RESULTS
UV-VIS absorption spectral changes upon
triazoloacridone–DNA-binding
The absorption spectra of C-1305 and the structurally related
biologically inactive C-1533 compound are shown on
Figures2A and3A.Binding ofC-1305 andC-1533 todifferent
DNA substrates (calf thymus DNA, [poly(dA–dT)]2 and
[poly(dG–dC)]2) revealed a marked hypochromic shifts in
absorption for triazoloacridone derivatives with maxima at
407 and 421 nm for C-1305, and 419 nm for C-1533. Bath-
ochromic shift was also observed for C-1305 spectra with a
3 nm shift for both peaks (407 and 421 nm) with ctDNA and
[poly(dG–dC)]2 whereas a 3 nm shift could be observed only
for 421 nm peak. No bathochromic shift was obtained for
C-1305 with [poly(dA–dT)]2. These results show that the
two compounds clearly bind to DNA and form stable com-
plexes with both AT and GC polymers.
CD
CD spectra were recorded at ﬁxed drug concentrations of
C-1305 and C-1533 and increasing concentrations of DNA
and are shown in Figures 2B and 3B. These spectra cover a
wide range of drug–DNA nucleotide ratios (ranging from 7:1
to 0.2:1). These results reveal a very distinct behavior of
C-1305 to different types of DNA (Figure 2B) compared
with C-1533 (Figure 3B). Compound C-1533 gave very
weak CD signals at 420–450 nm for ctDNA with no major
differences in CD signals for [poly(dA–dT)]2 and [poly(dG–
dC)]2 homopolymers. In striking contrast, for the biologically
active C-1305 derivative we observed a strong increase of the
CD signal at 305–365 nm, a decrease at 375–415 nm and an
increase at 430–470 nm. It is also possible to distinguish three
isodichroic crossovers closely positioned to isosbestic points
for absorption measurements. The CD amplitude of these
bands differs between DNA substrates, the strongest signal
was observed for calf thymus DNA that contains comparable
Figure 2. Absorption (A) and CD spectra (B) of C-1305 in the presence of
increasing concentrations of DNA (calf thymus DNA, [poly(dA–dT)]2 and
[poly(dG–dC)]2). DNA titration of the drug was performed in BPE buffer at
pH 7.1. To 1 ml of drug solution of 20 mM for absorption measurement and
50 mM for CD spectra, aliquots of a concentrated DNA solution were added.
Vertical arrows indicate the increase of phosphate-DNA/drug ratio, horizontal
arrows correspond to bathochromic shifts.
6038 Nucleic Acids Research, 2005, Vol. 33, No. 18proportions of AT (58%) and GC (42%) base pairs while
[poly(dA–dT)]2 gave the weakest signal. Although the exact
origin of the induced CD signals is not known, it is possible
that the negative band centered around 400 nm reﬂects the
intercalation of the drug between base pairs. Intercalating
agents frequently, but not systematically, generate negative
induced CD signals in their respective absorption band (33).
The magnitude of the negative CD bands is roughly identical
for ctDNA, [poly(dA–dT)]2 and [poly(dG–dC)]2, suggesting
that C-1305 can intercalate in all three sequence contexts,
which is in agreement with the absorption and ELD measure-
ments. This explanation is insufﬁcient when one considers the
behavior of C-1533. This inactive compound was also capable
of intercalating into DNA (see ELD data below) but did not
give rise to a negative CD band at 400 nm (Figure 3B). There-
fore, we are inclined to believe that the CD signals observed
with C-1305 in this region reﬂect the speciﬁc structural dis-
tortion of DNA induced by this compound (see DEPC data
below), rather than the intercalative binding process per se.
The intense positive CD bands centered at 330 and 450 nm
seen with ctDNA very likely reﬂect the unique capacity of this
compound to alter the DNA structure around intercalation
sites. The positive bands were very pronounced with
ctDNA and the GC polymer and much weaker for the AT
homopolymer.
ELD
To determine the binding mode and orientation of the bound
drug molecule to the long axis of DNA, we have used ELD.
The ELD spectra of studied drugs bound to ctDNA are shown
in Figure 4. These measurements were performed in a low
ionic strength buffer (1 mM sodium cacodylate), as required
for the ELD experiments due to the high electric ﬁeld applied
tothesolution)atahighDNA–drug ratio (P/D ¼ 20)toensure
that all drug molecules are bound to DNA. The intensity of
the ELD signal is a function of the degree of alignment of the
DNA molecules in the electric ﬁeld and for this reason, the
reduced dichroism (DA/A) values were measured at increasing
ﬁeld strengthat430nmforC-1305andC-1533 and440nmfor
m-AMSA (used as a reference acridine intercalator) are com-
parable to the one obtained for different types of DNA at
260 nm (Figure 4A). In all three cases, the reduced dichroism
DA/A was strongly negative in the drug absorption band,
which indicates an orientation of the chromophore perpendic-
ular to the helix axis (Figure 4B). The higher DA/A values
measured with the drug–DNA complexes compared to naked
DNA reﬂects drug-induced stiffening effects which would
favor the orientation of the DNA molecules in the electric
ﬁeld. This phenomenon is commonly seen with intercalating
agents (34). Altogether, the ELD data suggest that the studied
compounds are oriented parallel to the base pairs and strongly
supports the intercalative binding mode, independent of the
particular DNA substrate used (ct DNA, and both alternating
homopolymers).
DNA-binding affinity
To evaluate the DNA-binding afﬁnity of C-1305 a quantitative
analysis of the drug–DNA interaction was performed by SPR
(Figure 5) at constant temperature. Two 50 biotin-labeled hair-
pin oligomers containing a [AT]4 or [GC]4 tract were immo-
bilized on the sensor surface through streptavidin–biotin
coupling and blank ﬂow cell was used as a control (32). Rep-
resentative sensogram at different concentrations of C-1305
binding to the GC duplex is shown in Figure 5A. In the asso-
ciation phase of the experiment, a solution containing increas-
ing concentrations of the triazoloacridone derivatives (ranging
from 0.01 to 25 mM) was introduced, and the progress of drug–
DNA-binding was continuously monitored. The number of
C-1305 molecules bound to the [AT]4 oligonucleotide is
much lower than what is obtained for the [GC]4 oligonu-
cleotide, and the RU value for the [AT]4 oligonucleotide is
almost three times lower than that observed for the [GC]4
oligonucleotide (data not shown). Furthermore, C-1305
rapidly associated with DNA and formed stable drug–DNA
complexes. After addition of the buffer, the drug–DNA com-
plex rapidly dissociated. Compound C-1533 associated even
more rapidly with DNA, formed less stable drug–DNA com-
plexes that dissociated instantly (data not shown). The steady-
state RU values obtained for each compound were ﬁtted to the
equations as described in Materials and Methods. The binding
constants (K) are shown in the table on Figure 5B. The bind-
ing constants obtained for C-1305 clearly show a higher
Figure 3. Absorption (A) and CD spectra (B) of C-1533 in the presence of
increasing concentration of DNA (calf thymus DNA, [poly(dA–dT)]2 and
[poly(dG–dC)]2). DNA titration of the drug were performed in BPE buffer
at pH 7.1. To 1 ml of drug solution at 20 mM for absorption measurement
and50mMforCDspectra,aliquotsofaconcentratedDNAsolutionwereadded.
Vertical arrows indicate the increase of phosphate-DNA/drug ratio.
Nucleic Acids Research, 2005, Vol. 33, No. 18 6039preference of C-1305 toward GC sequences. The binding con-
stant for [GC]4 is almost 10 times higher than that measured
for [AT]4 with 3.0 · 10
5 versus 4.9 · 10
4 (M
 1). In contrast,
the C-1533 derivative exhibits much weaker binding ability,
with almost 10 times lower binding afﬁnity constant for both
[AT]4 and [GC]4 although some preference toward GC
sequences could be observed (Figure 5B). Data obtained
with SPR are in agreement with the results obtained with
other techniques, where C-1305 displayed higher DNA-
binding ability compared to C-1533.
DNase I footprinting for sequence selectivity
of drug binding
DNase I footprinting is one of the classic methods to inves-
tigate the in vitro sequence-speciﬁc interaction of drug with
DNA (35). We have compared the sequence selectivity of
triazoloacridone derivatives with compound Hoechst 33258,
a well-deﬁned DNA minor groove binder with high speciﬁcity
for AT sequences (36). In this study, a 176 bp DNA fragment
from pBS plasmid DNA was used, covering a wide range of
possible base pair combinations. For Hoechst 33258, we
observed two main regions of DNA cleavage inhibition,
mainly in AT-rich region (50-GTTAA-30 and 50-CTTTTG-
30) (see Supplementary Figure 1). In contrast, both studied
triazoloacridonesgave nosequence-speciﬁc DNase Ifootprint.
We could only observe a non-speciﬁc inhibition of DNase I
activitywith increasing concentrations ofC-1305 (10–50 mM),
whereas compound C-1533 had practically no effect.
Chemical probing
To further elucidate the potential sequence-speciﬁc interaction
of C-1305 with purine-rich DNA regions, we carried out a
series of chemical probing experiments with DEPC. Chemical
probing of DNA with DEPC is based on diethylpyrocarbonate
alkylation of the N7 residue of purines in the major groove of
DNA, resulting in destabilization of phosphodiester bonds in
the presence of piperidine (22). With increasing concentra-
tions of C-1305, we observed a markedly increased DEPC
Figure 4. ELD data for drug binding to DNA. Dependence of the reduced dichroism DA/A on the wavelength (A) and electric field strength (B) for DNA (open
square), m-AMSA (closed square) and triazoloacridone derivatives C-1305 (open circle) and C-1533 (closed circle). Conditions: 13.6 kV/cm, P/D ¼ 20 (200 mM
DNA and 10 mM drug) (A) and DA/A was measured in absorption band of 440 nm for the DNA–amsacrine complexes (P/D ¼ 20), 430 nm for the
DNA–triazoloacridone derivative complexes (P/D ¼ 20) and 260 nm for the DNA alone (B). All measurements were performed in 1 mM sodium cacodylate
buffer, pH 7.0.
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lanes (Figure 6). At drug concentration as low as 100 nM,
we could observe DEPC-associated DNA cleavage at DNA
sites containing stretches of three consecutive guanines (posi-
tions from 44 to 65, modiﬁcation sites are indicated in Figure 6
with arrows). In some cases, the drug-mediated enhanced
reactivity of DEPC was observed at GG doublets (e.g. posi-
tions 25 and 33) but at these sites the band intensity is con-
siderably lower than at the GGG-triplets. The effect was
highly speciﬁc for C-1305 since the C-1533 triazoloacridone
derivative did not produce similar changes in DNA. Higher
DEPC reactivity in G-rich DNA regions induced by C-1305
was dose-dependent, and the maximum effect was observed at
50 mM. Comparative studies with a series of 12 other DNA
topoisomerase II inhibitors revealed that none of the tested
compounds were able to induce DNA cleavage in guanine
triplets (Figure 7). We identiﬁed a group of compounds
with the ability to speciﬁcally disturb DNA (bisantrene,
TAS-103, echinomycin and to a lesser extent, mitoxantrone),
but the DNA cleavage proﬁle (see schematic below the gel in
Figure 6) was completely different from the one obtained for
C-1305.
We also performed chemical probing with osmium
tetraoxide/pyridine that cleaves DNA speciﬁcally at thymines
and detects changes in DNA structure at AT-rich sequences.
We did not observe any enhanced reactivity of the osmium
tetraoxide/pyridine complex toward DNA for either C-1305 or
C-1533 (data not shown).
Affinity of C-1305 to different DNA substrates
To clarify whether induction of structural changes in DNA
structure by C-1305 is associated with its higher afﬁnity to
DNAcontainingG-triplets,weperformed meltingtemperature
studies and equilibrium microdialysis experiments with dif-
ferent DNA substrates. We speciﬁcally designed 7 oligonu-
cleotides (24 bp long), with comparable GC content of  50%,
which either contained G-triplets with different neighboring
nucleotides or ‘mutated’ G-triplets (see Table 2 for oligonu-
cleotide sequences). Both melting temperature studies as well
as microdialysis measurements showed no major differences
in DNA afﬁnity of C-1305 to studied oligonucleotides
(Figure 8). It follows that the induction of structural changes
inguaninetripletsisnotdirectlyassociatedwithhigherafﬁnity
of C-1305 to guanine-rich DNA.
Structure–activity relationship studies
for a series of acridones
We then wanted to deﬁne the structural elements that are
responsible for the unusual ability of C-1305 to induce struc-
tural changes in DNA at guanine triplets. To this end, we
selected a set of nine acridone derivatives that differ in
their chemical structures. There were four major differences
in the chemical structures of the studied compounds:
(i) changes in the aminoalkylamino side chain (a number of
methylene groups and substituent R1); (ii) substituent R2 in
position 8 of the acridone ring; (iii) presence or absence of the
methyl group at the nitrogen atom in position 5 of the acridone
ring (R3); and (iv) conversion of triazolo to imidazo ring
Figure5. SPRsensograms(A)forbindingofC-1305tothe[GC]4DNAhairpin
oligomer in HBS-EP buffer at 25 C. Table (B) represents equilibrium binding
constants of C-1305 and C-1533 to [AT]4 and [GC]4 DNA.
Figure 6. DEPC reactivity on the 176 bp DNA fragment. Experiments were
done in the presence of increasing concentrations of C-1305 and C-1533.
Digestion products were resolved on 8% polyacrylamide gel containing 7 M
urea. Control tracks contained no drug. Numbers on the left side of the gel
refer to the standard numbering scheme for the nucleotide sequence of the
DNA fragment based on comparison to the position of the guanines on
guanine-specific track. Arrows indicate dose-dependent sequence-specific
interaction of C-1305 in guanine-rich regions of DNA. G, guanine track; D,
DNA unmodified; C, control DNA.
Nucleic Acids Research, 2005, Vol. 33, No. 18 6041condensed with the acridone chromophore (X). The chemical
structures of all studied compounds are shown in Table 1.
We compared the sequence-speciﬁc interaction of triazolo-
and imidazoacridone compounds with the aforementioned
176 bp DNA fragment by chemical probing with DEPC. As
could be seen in Figure 9A, only the C-1305 derivative effec-
tively increased the reactivity of DNA with DEPC at guanine
triplets compared to drug-free lanes. We also compared the
relative effect induced by different compounds by densitome-
try analysis of band intensity corresponding to guanine 46
which is the central guanine of the guanine triplet (indicated
with an arrow in Figure 9B). This analysis showed  20-fold
increase in DNA cleavage induced by C-1305 and only minor
effect of three other tested compounds. These compounds
include two triazoloacridones C-1297, C-1234 and imida-
zoacridone C-1371. These ﬁndings suggest that a hydroxyl
group in position 8 of the acridone chromophore is crucial
for the induction of speciﬁc changes in the DNA structure by
C-1305, that result in increased reactivity with DEPC.
A substantial fraction of compound C-1305 at pH > 7i s
present as zwitterion, with a protonated terminal nitrogen
atom in the side chain and a deprotonated hydroxyl group
at position 8 of the chromophore (see Supplementary Figure
2). Therefore, we studied the inﬂuence of pH on drug-induced
DEPCreactivity.AtacidicpH(pH < 7),wecouldobserveonly
very low DEPC reactivity at guanine triplets in the presence
of C-1305 (Figure 10). In contrast, at pH 7 and higher, we
observed increasing DEPC reactivity at guanine triplets of
DNA incubated with C-1305. This could not be explained
by altered DNA-binding afﬁnity of C-1305 at different pH
since we observed no apparent change in stabilization of
the secondary DNA structure by C-1305 with increasing pH
as revealed by DNA melting temperature studies (data not
shown). DNA alone did not show increased DEPC reactivity
at different pH since DNA cleavage was observed in the
absence of drug.
Molecular modeling
Based on our experimental data, we concluded that C-1305
binds to DNA and induces speciﬁc structural changes within
guanine triplets. However, the exact position of C-1305 in the
drug–DNA complex as well as the way the DNA structure is
perturbed upon ligand binding is not known. Formally, the
compound can intercalate outside (‘on top of’) the G-triplet
or it can be localized inside the G-triplet. In addition, in both
Figure 7. Effect of DNA topoisomerase inhibitors on DEPC reactivity toward
the 176 bp DNA fragment. Digestion products were resolved on 8% polyacry-
lamide gel containing 7 M urea. Control tracks contained no drug. Numbers on
theleftsideofthegelrefertothestandardnumberingschemeforthenucleotide
sequence of the DNA fragment based on comparison to the position of the
guanines on guanine-specific track.
Figure 8. (A) Sequence-dependent stabilization of the DNA secondary struc-
ture in the presence of C-1305. The graph represents variation of the melting
temperature differences DTm (T m
drug–DNA complex  T m
DNA alone, in degrees)
determined for complexes between C-1305 and different DNA substrates
(see Table 2 for oligonucleotide sequences) in BPES buffer pH 7.1. Gray
and black bars correspond to drug–DNA ratios of 0.5:1 and 1:1, respectively.
(B) Sequence-dependent binding affinity of C-1305 obtained by the competi-
tion microdialysis assay in BPES buffer. All experiments were carried out in
duplicates at least twice. Results are presented as means ± SD.
6042 Nucleic Acids Research, 2005, Vol. 33, No. 18situations there are two possible orientations of the drug due to
the asymmetry of the planar chromophore. We applied theo-
retical chemistry and molecular modeling analysis in order to:
(i) determine the position of C-1305 inside the drug–DNA
complex that is energetically favorable, (ii) analyze the struc-
tural changes that occur upon drug–DNA complex formation,
and (iii) investigate the molecular basis of the unusual
DEPC reactivity at N7 atom of the middle guanine of the
G-triplet.
To compare the energetics of C-1305 binding at the two
distinct drug–DNA interaction sites, the MM–PBSA free
energy calculations were performed on time evolving data
(MD). Calculations revealed a difference of  5 kcal/mol
between the two studied complexes and in the more energeti-
cally favorable model, the drug was positioned inside the G-
triplet. For this drug location, we analyzed structural changes
in DNA induced by the intercalated drug within a G-triplet.
CompoundC-1305induced stronger structuralchangesingua-
nine triplets at higher pH suggesting that drug protonation/
deprotonation might be important for this drug-speciﬁc effect.
Therefore, we compared structural changes induced by C-
1305 with protonated terminal nitrogen atom of the side
chain and the zwitterionic form of the drug, with both a pro-
tonated nitrogen in the side chain and a deprotonated hydroxyl
group of the chromophore. Comparison of the structure of
drug–DNA complexes for protonated and zwitterionic
forms of C-1305 revealed signiﬁcant differences. For C-
1305, which is only protonated at the terminal nitrogen
atom of the side chain, the hydroxyl group in the chromophore
is able to form hydrogen bond with O40 atom of deoxyribose in
the ‘upper’ cytidine of the G-triplet (Figure 11a, arrow). In
striking contrast, this is not possible for the zwitterionic form
of C-1305 where the very same O40 atom now forms hydrogen
bond with the protonated terminal nitrogen atom of the side
chain of C-1305 (Figure 11b, arrow). This hydrogen bonding
leads to immobilization of the side chain in the minor groove
and produces a substantial distortion in base pairing between
‘upper’ guanine and cytosine. Deprotonation of the hydroxyl
Figure 9. Effect of triazolo- and imidazoacridone derivatives on DEPC reac-
tivity toward a 176 bp DNA fragment (A) Optical density analysis of specific
drug–DNA interaction sites. (B) Arrow indicates the position of the band on
which the cleavage intensity for each compound was measured by densitome-
try. The graph representsan increaseof the cleavage at guaninesites compared
to control/untreated DNA.
Figure 10. InfluenceofpHonDEPCreactivitytowarda176bpDNAfragment
incubatedinthepresenceofC-1305(A)Experimentswerecarriedoutin10mM
Tris–HCl/NaCl buffer with increasing pH value (ranging from 5.55 to 9.0).
Control tracks with DNA (D) were added for each pH value and contained no
drug. G, guanine track; C, DNA unmodified; D, control DNA. 1, 20–1 and
20mMC-1305.Opticaldensityanalysisofspecificdrug–DNAinteractionsites.
(B)Arrowindicatesthepositionofthebandonwhichthecleavageintensityfor
each compound was measured by densitometry. The graph represents an
increase of the cleavage at guanine site over control/untreated DNA.
Nucleic Acids Research, 2005, Vol. 33, No. 18 6043group allows the drug chromophore to re-position in such a
way that the nitrogen atoms of the triazole ring are aligned
with the N7 atoms of the three guanines. Simulation with C-
1305, which had protonated hydroxyl oxygen showed that the
hydrogen bonding between OH group and O40 atom of
deoxyribose in cytidine, prevents the ligand to adopt the
same position as the zwitterionic form of the compound
(compare structures B and C in Figure 11). In both cases,
drug intercalation leads to signiﬁcant distortions of the
phosphate-sugar backbone and widening of both the major
and the minor DNA grooves in order to minimize conforma-
tional hindrances. Interestingly, for the zwitterionic form of
C-1305 intercalated into DNA we observed a strong exposure
to the solvent of the N7 atom of the middle guanine in the
G-triplet (Supplementary Figure 3, structure B, arrow).
Analysis of the MEP distribution in the major DNA groove
upon drug intercalation showed that the N7 atoms of three
consecutive guanines in the G-triplet generate a long patch of
the negative potential (structure A0, Figure 11). Since the
intercalated zwitterionic form of C-1305 locates its triazole
ring in close proximity to these atoms, this leads to the pro-
duction of even stronger local negative electrostatic potential
within the major groove, which is not observed for C-1305
with a protonated hydroxyl oxygen at position 8 (compare
structures A0,B 0 and C0, Figure 11).
DISCUSSION
Among the antitumor drugs used in the treatment of human
cancers, a signiﬁcant portion is comprised of DNA interacting
compounds. Search for new low molecular weight ligands that
could speciﬁcally bind to particular DNA sequences has been
carried out for years, in the hope that new therapeutics could
be found that would selectively modulate aberrant gene
Figure 11. Formation of the hydrogen bond between the O40 atom of the ribose in the ‘upper’ cytidine (arrow) and deprotonated hydroxyl group at position 8 of
C-1305 of the zwitterionic form of the drug (a) and protonated terminal nitrogen atom in the side chain of C-1305 (b). Arrow marks O40 atom of deoxyribose in
the ‘upper’ cytosine of the G-triplet. Structures of the DNA fragment without drug and C-1305:DNA complexes (A) where the compound is intercalated inside
the G-triplet as a zwitterionic form (B) and with protonated terminal nitrogen of the side chain only (C). Guanine residues from the G-triplet are colored by name,
nitrogenatomsN7ofguaninesinblue.CompoundC-1305isshowninyellowwithnitrogensfromtriazoleringaremarkedbluewhilehydroxyloxygenismarkedred,
othernucleotidesoftheDNAfragmentareindicatedincyan.Thehydroxylgroupatposition8ofthedrugchromophoreismarkedwithanarrow.Thedistributionof
MEP on equipotential surfaces for the DNA (A0) and both studied C-1305:DNA complexes (B0 and C0). Colors correspond to potential values, negative potential at
 5 kcal/mol is shown in red, positive potential at +5 kcal/mol is shown in blue.
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standing of ligand-DNA recognition, these efforts have so
far been only partially successful and only relatively few com-
pounds show high DNA sequence-speciﬁcity. Notable excep-
tions are at least some bis-intercalators and DNA alkylators
[for recent review see (37)]. Compounds that bind selectively
to a particular DNA sequence of three nucleotides or longer
are sandramycin and luzopeptins, that recognize 50-CATG
sequence (38,39), as well as ditercalinium that shows speci-
ﬁcity to 50-CGCG sequence (40). Interestingly, aﬂatoxin has
been shown to intercalate within G-triplets and to bind cova-
lently at the middle guanine of the G-triplet (41).
Our previous studies have shown that C-1305 is an unusual
inhibitor of DNA topoisomerase II in vitro and in tumor cells
(3). At cytotoxic doses, C-1305 produces only low levels of
unusually toxic cleavable complexes compared to classic
topoisomerase II inhibitors such as m-AMSA. One of the
possible explanations for this phenomenon could be that
C-1305 stimulates formation of cleavable complexes in spe-
ciﬁc DNA regions resulting in the formation of DNA damage
that is very toxic to cells. In the present study, we systemati-
cally characterized the interactions of C-1305 and other tria-
zoloacridones with DNA in vitro. We were particularly
interested in a possible sequence-speciﬁc DNA-binding of
C-1305 or production of structural changes in DNA, that
could explain the unusual biological properties of this com-
pound. We here show that C-1305 binds to DNA with limited
sequence-speciﬁcity but induces very unusual structural
changes in DNA sequences containing guanine triplets. Com-
parison with 22 other topoisomerase inhibitors and DNA inter-
acting agents showed that this structural perturbation was
speciﬁc for the C-1305 compound. This ﬁnding is particularly
interesting, since to the best of our knowledge, this property is
unique among anticancer compounds that bind to DNA.
DEPC probing showed prominent changes in the secondary
DNA structure within regions containing guanine triplets, but
had no effect on adenine-rich sequences. DEPC reacts with the
N7 atoms of purines in the major groove (21). The structural
changes in DNA induced by C-1305 binding principally per-
turb the major groove geometry in DNA regions containing
guanine triplets. It is also worth noting, that C-1305 did not
produce signiﬁcant DEPC reactivity within a run of 12 con-
secutive GC pairs or GAGG sequence, that are present in the
studied DNA fragment. These ﬁndings strongly suggest that
regions with consecutive guanine residues and not just
purine-rich triplets are absolutely required for the induction
of structural changes in DNA by C-1305. However, the most
pronounced structural DNA perturbations induced by C-1305
occurred in GGG-triplets.
Based on molecular modeling analysis, we predict that
C-1305 intercalates between the ﬁrst or the last guanine in
thestretchofthreeguanines,which leadstolocalunwindingof
DNA and widening of both the minor and the major DNA
grooves. These structural changes are associated with changes
in the structure of the phosphate backbone and the positions of
the guanineresidues within the G-triplet, resulting inincreased
reactivity of the N7 guanine atoms with the chemical probe
DEPC. Our model predicts that the most prominent change in
the position of the N7 atom occurs at the middle guanine of
the G-triplet. This is in full agreement with our experimental
data where densitometric analysis indicated that the middle
guanine is the most reactive to DEPC, compared to other
guanine residues of the G-triplet. It is also possible that the
strong and localized negative electrostatic potential, that is
present in the major groove once the drug is intercalated
within guanine triplet, may facilitate chemical reaction of
carbethoxylation by DEPC.
AfundamentalquestioniswhyC-1305,which isarelatively
small molecular weight DNA intercalator, is able to produce
such a speciﬁc effect on the secondary DNA structure within
very deﬁned regions i.e. guanine triplets. Mixed-function
DNA intercalators, such as the studied triazoloacridone
C-1305, with ﬂat chromophore moiety combined with an
aminoalkyl side chain, intercalate into DNA in the minor
groove and cover a maximum of 2–3 nt with the side chain
located in the minor groove. It appears that the speciﬁc effect
of C-1305 within guanine triplets is not directly linked to a
higher afﬁnity of the drug to DNA, as revealed by DNA
melting temperature studies and microdialysis experiments
with DNA substrates containing three consecutive guanine
residues. Based on the structure–activity relationship for a
group of acridones used in our studies as well as molecular
modeling studies we propose that unique properties of C-1305
result from its ability to combine speciﬁc structural features
of a typical DNA intercalator with the synergistic contribu-
tion of electrostatic interactions of the charged (zwitterionic)
form of C-1305.
We were able to deﬁne three structural features that are
absolutely required for C-1305 to induce the unusual structural
perturbation in guanine triplets. These include: (i) triazole ring
in the chromophore; (ii) hydroxyl group at position 8 of the
chromophore; and (iii) aminoalkyl side chain with three
methylene groups and methyl groups at the terminal nitrogen
atom. It should be noted that among all studied tria-
zoloacridone derivatives this unique combination of structural
features is only present in compound C-1305. Based on our
results, we propose a molecular basis to explain the contribu-
tion of each of these three. First, when the drug chromophore
intercalates between base pairs a sufﬁciently long side chain
(with three methylene groups in the aminoalkyl chain) is
needed to allow the chromophore to penetrate DNA helix
and the triazole ring of the chromophore can interact within
the major groove of DNA. Second, at physiological pH our
compound possesses a fully protonated terminal nitrogen atom
on the side chain and a substantial fraction of the drug (more
than 50% of the total drug molecules at pH 7.9) is present as a
zwitterion i.e. with a deprotonated hydroxyl group at position
8 of the chromophore. The presence of deprotonated hydroxyl
group allows re-positioning of the chromophore within the
drug–DNA complex and, when C-1305 is located within
G-triplet, the triazole ring can become aligned with three
N7 atoms of guanines. Third, the protonated terminal nitrogen
of the side chain forms a hydrogen bond with O40 atom of the
ribose and relatively non-bulky substitutents, such as methyl
groups at the terminal nitrogen of the side chain, do not
obstruct this interaction. There is a very interesting question
as to whether zwitterionic form of C-1305 can intercalate into
DNA or if the deprotonation of the hydroxyl group occurs only
after C-1305 becomes intercalated into DNA. We would
expect that the presence of the negative charge on the chro-
mophore in the zwitterionic form could lead to electrostatic
repulsion during initial stages of DNA intercalation. Further
Nucleic Acids Research, 2005, Vol. 33, No. 18 6045studies are required to fully clarify the role of electrostatic
interactions in DNA-binding by C-1305.
The ability of C-1305 to induce structural perturbations in
guanine triplets could have important biological conse-
quences. Many functional DNA regions in the human genome
contain guanine triplets or guanine-rich sequences. These
include telomeres, centromeres and GC-rich gene promoter
regions. Therefore, it is possible that the structural changes
induced upon C-1305 binding might interfere with function-
ality of these DNA regions. Vertebrate telomeric sequences
contain guanine triplets and may fold into higher order struc-
tures, called G-quadruplexes (42). It is possible that compound
C-1305 could speciﬁcally bind telomeric DNA and studies are
under way in our laboratory to evaluate the afﬁnity of the drug
for telomeric sequences or G-quartet structures. Another pos-
sibility is that the afﬁnity of regulatory proteins, such as tran-
scription factors, may be altered when C-1305 is bound to
promoter regions that contain guanine triplets due to changes
both in the local DNA structure and distribution of MEP. This
could lead to changes in gene expression proﬁles which would
most likely be limited to those genes that are regulated by
guanine-rich promoters. Finally, production of structural
changes by C-1305 in speciﬁc DNA regions with guanine
triplets might be associated with the inhibition of topoiso-
merase II activity by this compound. Structural changes in
guanine triplets might lead to preferential stabilization of
cleavable complexes in these regions which, in turn, could
result in region-speciﬁc DNA cleavage in telomeres, cen-
tromeres or guanine-rich promoters. Interestingly, etoposide
has been shown to induce DNA damage in both telomeric and
centromeric DNA (43,44).
Together, here we report that the antitumor triazoloacridone
compound C-1305 binds to DNA and induces unusual struc-
tural changes speciﬁcally in DNA sequences containing gua-
nine triplets. Comparison with 22 topoisomerase inhibitors
and other DNA interacting agents, including a series of struc-
turally related triazoloacridones showed that the structural
perturbation of guanine-rich regions was speciﬁc for C-
1305. We suggest that the structural perturbations induced
by C-1305 play an important role in the cytotoxic and anti-
tumor effects of this unique compound.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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